Insiders Vivesto AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.274 ^SEK	+2.05%		+1.48%	-32.76%

Jul. 01	Vivesto AB Receives Positive Cantrixil Preclinical Efficacy Data	CI
May. 23	Vivesto AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Vivesto AB Announces Composition of Nomination Committee	Nov. 23	CI
Vivesto's New CEO to Formally Assume Role in January 2023	22-12-28	MT
Vivesto AB Announces Appoints Erik Kinnman as CEO, Effective from January 23, 2023	22-12-28	CI
Vivesto AB Announces Chief Executive Officer Changes, Effective No Later Than May 20, 2023	22-11-30	CI
Vivesto Names Sprint Bioscience Boss as New CEO; Shares Down 6%	22-11-21	MT
Vivesto AB Appoints Erik Kinnman as CEO	22-11-21	CI
Vivesto AB Appoints Nomination Committee for 2023	22-11-21	CI
Swedish Drugmaker Vivesto's Acting CEO to Leave Role	22-11-04	MT
Vivesto AB Announces Resignation of Christer Nordstedt as Acting Ceo, Effective 30 November 2022	22-11-03	CI
Vivesto Appoints Acting CEO	22-07-21	MT
Vivesto AB Appoints Christer Nordstedt as Acting CEO	22-07-21	CI
Vivesto AB Announces CEO Francois Martelet Agrees on Ending the Employment Relationship, Effective July 21, 2022	22-06-13	CI
Vivesto AB Announces Executive Changes	22-05-25	CI
Vivesto AB Appoints Daniel Tesfa as Chief Medical Officer	22-04-11	CI
Oasmia Pharmaceutical AB Announces Appointment of Nomination Committee	21-12-03	CI
Oasmia Pharmaceutical AB Announces Executive Appointments	21-08-26	CI
Oasmia Pharmaceutical AB Elects Andrea Buscaglia as Members of the Board of Directors	21-05-27	CI
Oasmia Pharmaceutical Appoints Dr. Heidi B. Ramstad as Chief Medical Officer	21-02-01	CI
Oasmia Pharmaceutical AB Announces Board Appointments	20-11-20	CI
Oasmia Pharmaceutical AB Appoints Peter Selin as Chief Business Officer	20-08-10	CI

No results for this search